Abstract
Expression of neurotrophin receptors of the tyrosine kinase receptor (Trk) family is an important prognostic factor in solid tumors including neuroblastoma. High expression of TrkA (NTRK1) is associated with a favorable biology and outcome of neuroblastoma, whereas TrkB (NTRK2) is expressed on aggressive neuroblastomas with unfavorable outcome. To gain new insights into the global gene expression program resulting in these divergent biological phenotypes, we stably expressed either TrkA or TrkB in the human SH-SY5Y neuroblastoma cell line. Gene expression profiles were obtained from parental cells and transfectants activated by their ligands in a time course over 24 h using oligonucleotide microarrays. Basal activation of Trk receptors in the absence of exogenous ligand was sufficient to induce broad and divergent genetic changes. Global gene regulation following external ligand stimulation was surprisingly similar in SY5Y-TrkA and SY5Y-TrkB cells except for the differential expression of distinct novel target genes. Consistent with their divergent biological phenotype, SY5Y-TrkA cells were characterized by upregulation of proapoptotic genes and angiogenesis inhibitors, whereas SY5Y-TrkB cells demonstrated upregulation of genes involved in invasion or therapy resistance. We suggest that the transcriptional program of neuroblastoma cells is modulated by Trk-receptor expression and basal activation rather than by ligand-induced activation. Fine-tuning of the malignant phenotype may be achieved by additional ligand stimulation with subsequent activation of a few specific genes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- Vec:
-
empty vector control
- Pcc:
-
Pearson correlation coefficient
- MDR:
-
multidrug resistance
- MRP:
-
multidrug resistance-associated protein
- P-gp:
-
P-glycoprotein
- MCSP:
-
melanoma-associated chondroitin sulfate proteoglycan
- VEGF:
-
vascular endothelial growth factor
- bFGF:
-
basic fibroblast growth factor
- sFlt:
-
soluble fms-related tyrosine kinase (vascular endothelial growth factor receptor)
- CM:
-
conditioned medium
- IGF-I:
-
insulin-like growth factor I
- IGFBP-3:
-
insulin-like growth factor receptor binding protein 3
- TrkA:
-
B, tyrosine kinase receptor A, B
- NGF:
-
nerve growth factor
- BDNF:
-
brain-derived neurotrophic factor
- RIA:
-
radioimmunoassay
References
Biedler JL, Helson L and Spengler BA . (1973). Cancer Res., 33, 2643–2649.
Conover JC and Yancopoulos GD . (1997). Rev. Neurosci., 8, 13–27.
Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V, Le Bourhis X, Boilly B, Peyrat JP and Hondermarck H . (2001). J. Biol. Chem., 276, 17864–17870.
Eggert A, Brodeur GM and Ikegaki N . (2000a). Biotechniques, 28, 681–691.
Eggert A, Grotzer MA, Ikegaki N, Liu XG, Evans AE and Brodeur GM . (2002). Cancer Res., 62, 1802–1808.
Eggert A, Ikegaki N, Liu X-G, Chou TT, Lee VM, Trojanowski JQ and Brodeur GM . (2000b). Oncogene, 19, 2043–2051.
Emanuelsson O, Nielsen H, Brunak S and von Heijne G . (2000). J. Mol. Biol., 300, 1005–1016.
Fambrough D, McClure K, Kazlauskas A and Lander ES . (1999). Cell, 97, 727–741.
Ferrone S and Wang X . (2001). Recent Results Cancer Res., 158, 231–235.
Ferry Jr RJ, Cerri RW and Cohen P . (1999a). Horm. Res., 51, 53–67.
Ferry Jr RJ, Katz LE, Grimberg A, Cohen P and Weinzimer SA . (1999b). Horm. Metab. Res., 31, 192–202.
Fujiwara Y, Sugimoto Y, Kasahara K, Bungo M, Yamakido M, Tew KD and Saijo N . (1990). Jpn. J. Cancer Res., 81, 527–535.
Haapasalo A, Saarelainen T, Moshnyakov M, Arumae U, Kiema TR, Saarma M, Wong G and Castren E . (1999). Oncogene, 18, 1285–1296.
Haber M, Bordow SB, Gilbert J, Madafiglio J, Kavallaris M, Marshall GM, Mechetner EB, Fruehauf JP, Tee L, Cohn SL, Salwen H, Schmidt ML and Norris MD . (1999). Oncogene, 18, 2777–2782.
Ho R, Eggert A, Hishiki T, Minturn JE, Ikegaki N, Foster P, Camoratto AM, Evans AE and Brodeur GM . (2002). Cancer Res., 62, 6462–6466.
Iida J, Pei D, Kang T, Simpson MA, Herlyn M, Furcht LT and McCarthy JB . (2001). J. Biol. Chem., 276, 18786–18794.
Iyer VR, Eisen MB, Ross DT, Schuler G, Moore T, Lee JC, Trent JM, Staudt LM, Hudson Jr J, Boguski MS, Lashkari D, Shalon D, Botstein D and Brown PO . (1999). Science, 283, 83–87.
Jaboin J, Kim CJ, Kaplan DR and Thiele CJ . (2002). Cancer Res., 62, 6756–6763.
Kaplan DR and Miller FD . (2000). Curr. Opin. Neurobiol., 10, 381–391.
Kim CJ, Matsuo T, Lee KH and Thiele CJ . (1999). Am. J. Pathol., 155, 1661–1670.
Lee FS and Chao MV . (2001). Proc. Natl. Acad. Sci. USA, 98, 3555–3560.
Leventhal PS, Randolph AE, Vesbit TE, Schenone A, Windebank A and Feldman EL . (1995). Exp. Cell Res., 221, 179–186.
Lou X, Yano H, Lee F, Chao MV and Farquhar MG . (2001). Mol. Biol. Cell., 12, 615–627.
Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH and Stampfer MJ . (1999). J. Natl. Cancer Inst., 91, 620–625.
Matsumoto K, Wada RK, Yamashiro JM, Kaplan DR and Thiele CJ . (1995). Cancer Res., 55, 1798–1806.
McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD, Ball DW, Baylin SB and Nelkin BD . (1999). Proc. Natl. Acad. Sci. USA, 96, 4540–4545.
Meyer GE, Shelden E, Kim B and Feldman EL . (2001). Oncogene, 20, 7542–7550.
Micera A, Vigneti E, Pickholtz D, Reich R, Pappo O, Bonini S, Maquart FX, Aloe L and Levi-Schaffer F . (2001). Proc. Natl. Acad. Sci. USA, 98, 6162–6167.
Middlemas DS, Kihl BK and Moody NM . (1999a). J. Neurooncol., 45, 27–36.
Middlemas DS, Kihl BK, Zhou J and Zhu X . (1999b). J. Biol. Chem., 274, 16451–16460.
Mosmann T . (1983). J. Immunol. Meth., 65, 55–63.
Muragaki Y, Chou TT, Kaplan DR, Trojanowski JQ and Lee VM-Y . (1997). J. Neurosci., 17, 530–542.
Nakagawara A, Arima-Nakagawara M, Scavarda NJ, Azar CG, Cantor AB and Brodeur GM . (1993). N. Engl. J. Med., 328, 847–854.
Nakagawara A, Azar CG, Scavarda NJ and Brodeur GM . (1994). Mol. Cell. Biol., 14, 759–767.
Neaud V, Hisaka T, Monvoisin A, Bedin C, Balabaud C, Foster DC, Desmouliere A, Kisiel W and Rosenbaum J . (2000). J. Biol. Chem., 275, 35565–35569.
Norris MD, Bordow SB, Marshall GM, Haber PS, Cohn SL and Haber M . (1996). N. Engl. J. Med., 334, 231–238.
Orike N, Thrasivoulou C, Wrigley A and Cowen T . (2001). J. Neurobiol., 47, 295–305.
Patapoutian A and Reichardt LF . (2001). Curr. Opin. Neurobiol., 11, 272–280.
Penuel E, Akita RW and Sliwkowski MX . (2002). J. Biol. Chem., 277, 28468–28473.
Scala S, Wosikowski K, Giannakakou P, Valle P, Biedler J, Spengler BA, Lucarelli E, Bates S and Thiele CJ . (1996). Cancer Res., 56, 3737–3742.
Singleton JR, Randolph AE and Feldman EL . (1996). Cancer Res., 56, 4522–4529.
Smith AJ, van Helvoort A, van Meer G, Szabo K, Welker E, Szakacs G, Varadi A, Sarkadi B and Borst P . (2000). J. Biol. Chem., 275, 23530–23539.
Sturn A, Quackenbush J and Trajanoski Z . (2002). Bioinformatics, 18, 207–208.
Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES and Golub TR . (1999). Proc. Natl. Acad. Sci. USA, 96, 2907–2912.
Teitler M, Herrick-Davis K and Purohit A . (2002). Curr. Top. Med. Chem., 2, 529–538.
Vaudry D, Stork PJ, Lazarovici P and Eiden LE . (2002). Science, 296, 1648–1649.
Acknowledgements
This work was supported by grants from the Deutsche Krebshilfe (AE), the German National Genome Research Cancer Network (NGFN/BMBF) and IFORES (AE, AS), the National Institutes of Health Grant CA-94194 and the Audrey E Evans Endowed Chair (GMB). We thank Affymetrix Inc. for providing additional microarray chips; Soldano Ferrone and Novartis for providing the MCSP antibody; Tomoro Hishiki for providing the pLNCX2-TrkB construct; Helmut Augustin for performing the sFlt ELISA; Helena Pavlakovic, Ellen Mahlow, Andrea Drothler and Stephanie Paschen for excellent technical assistance, Anja Marr and Johannes Hüsing for helpful discussions regarding statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Oncogene website (http://www.nature.com/onc).
Rights and permissions
About this article
Cite this article
Schulte, J., Schramm, A., Klein-Hitpass, L. et al. Microarray analysis reveals differential gene expression patterns and regulation of single target genes contributing to the opposing phenotype of TrkA- and TrkB-expressing neuroblastomas. Oncogene 24, 165–177 (2005). https://doi.org/10.1038/sj.onc.1208000
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208000
Keywords
This article is cited by
-
Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities
Current Treatment Options in Oncology (2021)
-
N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma
Scientific Reports (2020)
-
The Evolving Diagnostic and Treatment Landscape of NTRK-Fusion-Driven Pediatric Cancers
Pediatric Drugs (2020)
-
Chronic Intermittent Hypobaric Hypoxia Pretreatment Ameliorates Ischemia-Induced Cognitive Dysfunction Through Activation of ERK1/2-CREB-BDNF Pathway in Anesthetized Mice
Neurochemical Research (2017)
-
Mutational dynamics between primary and relapse neuroblastomas
Nature Genetics (2015)